| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 7,020 | $40 | $266.8K |
| J0897 | Injection, denosumab, 1 mg | 4,860 | $20 | $92.3K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 430 | $110 | $45.5K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 21,800 | $1 | $43.6K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 210 | $150 | $31.6K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 30,750 | $1 | $30.8K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 200 | $120 | $23.3K |
| 99205 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider… | 90 | $190 | $16.7K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 180 | $80 | $15.1K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 110 | $100 | $10.7K |